0000950170-24-055089.txt : 20240508 0000950170-24-055089.hdr.sgml : 20240508 20240508081905 ACCESSION NUMBER: 0000950170-24-055089 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20240508 ITEM INFORMATION: Other Events FILED AS OF DATE: 20240508 DATE AS OF CHANGE: 20240508 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PRECISION BIOSCIENCES INC CENTRAL INDEX KEY: 0001357874 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38841 FILM NUMBER: 24924364 BUSINESS ADDRESS: STREET 1: 302 EAST PETTIGREW STREET STREET 2: SUITE A-100 CITY: DURHAM STATE: NC ZIP: 27701 BUSINESS PHONE: 919-314-5512 MAIL ADDRESS: STREET 1: 302 EAST PETTIGREW STREET STREET 2: SUITE A-100 CITY: DURHAM STATE: NC ZIP: 27701 8-K 1 dtil-20240508.htm 8-K 8-K
false0001357874NASDAQ00013578742024-05-082024-05-08

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): May 8, 2024

Precision BioSciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-38841

20-4206017

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

302 East Pettigrew St., Suite A-100, Durham, North Carolina 27701

(Address of principal executive offices) (Zip Code)

(919) 314-5512

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common stock, par value $0.000005 per share

DTIL

The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 8.01. Other Events.

 

On May 8, 2024, Precision BioSciences, Inc. (the “Company”) has entered into a definitive subscription agreement, pursuant to which the Company agrees to issue and sell in a non-brokered private placement (the “Private Placement”) to certain members from its management (the “Investors”) 25,000 shares of its common stock, par value $0.000005 per share (the “Shares”), at an offering price of $12.00 per share, representing a 13.5% premium to the closing price of its common stock immediately preceding the signing of the subscription agreement. The aggregate gross proceeds from the Private Placement is approximately $300,000. The Private Placement is expected to close on May 8, 2024, subject to the satisfaction of customary closing conditions.

 

The Company intends to use the net proceeds of the Private Placement to fund ongoing research and development initiatives.

 

Investors include: (1) Michael Amoroso, President and Chief Executive Officer of the Company and a member of the Company’s board of directors, who agreed to purchase 8,334 Shares for an aggregate amount of $100,008, (2) Alex Kelly, Chief Financial Officer of the Company, who agreed to purchase 8,334 Shares for an aggregate amount of $100,008, (3) Dario Scimeca, General Counsel of the Company, who agreed to purchase 833 Shares for an aggregate amount of $9,996; and (4) Jeff Smith, Chief Research Officer of the Company, who agreed to purchase 833 Shares for an aggregate amount of $9,996.

 

The offer and sale of the Shares have not been, and will not be, registered under the Securities Act of 1933, as amended, or any other securities laws, and the ordinary shares cannot be offered or sold except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws. This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities, in any state or jurisdiction in which such offer, solicitation or sale of these securities would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

 

Forward-Looking Statements

 

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, the intended use of proceeds of the Private Placement, statements regarding to the timing and size of the Private Placement, the anticipated total gross proceeds from the Private Placement and other statements relating to the Private Placement. In some cases, you can identify forward-looking statements by terms such as “aim,” “anticipate,” “approach,” “believe,” “contemplate,” “could,” “designed”, “estimate,” “expect,” “goal,” “intend,” “look,” “may,” “mission,” “plan,” “possible,” “potential,” “predict,” “project,” “pursue,” “should,”, “strive”, “target,” “will,” “would,” or the negative thereof and similar words and expressions. Forward-looking statements are based on management’s current expectations, beliefs and assumptions and on information currently available to us. Such statements are neither promises nor guarantees, and involve a number of known and unknown risks, uncertainties and assumptions, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including, without limitation, risks and uncertainties associated with the consummation of the Private Placement, uncertainties related to market conditions, the satisfaction of customary closing conditions related to the Private Placement, the completion of the Private Placement on the anticipated terms or at all, general economic conditions and other risks identified from time to time in the reports the Company files with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as such factors may be updated from time to time in its other filings with the SEC, accessible on the SEC’s website at www.sec.gov. The forward-looking statements in this Current Report on Form 8-K speak only as of the date of this Current Report on Form 8-K, and the Company undertakes no obligation to update or revise any of the statements. The Company’s business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

 

 

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

 

 

 

 

PRECISION BIOSCIENCES, INC.

 

 

 

 

Date: May 8, 2024

 

By:

/s/ John Alexander Kelly

 

 

 

John Alexander Kelly

 

 

 

Chief Financial Officer

 

 

 EX-101.SCH 2 dtil-20240508.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink Pre-commencement Issuer Tender Offer Entity Address, State or Province Trading Symbol Soliciting Material Entity Address, City or Town Written Communications Entity Central Index Key CIK Entity Tax Identification Number Entity Registrant Name Registrant Name Entity Ex Transition Period Document Period End Date Period End Date Entity Address, Postal Zip Code Entity Incorporation, State or Country Code Local Phone Number City Area Code Pre-commencement Tender Offer Cover [Abstract] Cover Security Exchange Name Entity Emerging Growth Company Amendment Flag Amendment Securities Act File Number Entity Address, Address Line Two Entity Address, Address Line One Title of 12(b) Security Document Type Document Type XML 4 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Document And Entity Information
May 08, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 08, 2024
Entity Registrant Name Precision BioSciences, Inc.
Entity Central Index Key 0001357874
Entity Emerging Growth Company true
Securities Act File Number 001-38841
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 20-4206017
Entity Address, Address Line One 302 East Pettigrew St.
Entity Address, Address Line Two Suite A-100
Entity Address, City or Town Durham
Entity Address, State or Province NC
Entity Address, Postal Zip Code 27701
City Area Code 919
Local Phone Number 314-5512
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Ex Transition Period false
Title of 12(b) Security Common stock, par value $0.000005 per share
Trading Symbol DTIL
Security Exchange Name NASDAQ
EXCEL 5 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 6 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 7 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 9 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://precisionbiosciences.com/20240508/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:SecurityExchangeName - dtil-20240508.htm 8 dtil-20240508.htm dtil-20240508.xsd http://xbrl.sec.gov/dei/2023 false false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "dtil-20240508.htm": { "nsprefix": "dtil", "nsuri": "http://precisionbiosciences.com/20240508", "dts": { "inline": { "local": [ "dtil-20240508.htm" ] }, "schema": { "local": [ "dtil-20240508.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://precisionbiosciences.com/20240508/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_ea148707-b480-4212-bb12-d377a2cc96f6", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "dtil-20240508.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_ea148707-b480-4212-bb12-d377a2cc96f6", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "dtil-20240508.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://precisionbiosciences.com/20240508/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://precisionbiosciences.com/20240508/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://precisionbiosciences.com/20240508/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://precisionbiosciences.com/20240508/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://precisionbiosciences.com/20240508/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://precisionbiosciences.com/20240508/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://precisionbiosciences.com/20240508/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://precisionbiosciences.com/20240508/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://precisionbiosciences.com/20240508/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://precisionbiosciences.com/20240508/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "CIK", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://precisionbiosciences.com/20240508/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://precisionbiosciences.com/20240508/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://precisionbiosciences.com/20240508/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://precisionbiosciences.com/20240508/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://precisionbiosciences.com/20240508/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://precisionbiosciences.com/20240508/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://precisionbiosciences.com/20240508/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://precisionbiosciences.com/20240508/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://precisionbiosciences.com/20240508/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://precisionbiosciences.com/20240508/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://precisionbiosciences.com/20240508/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://precisionbiosciences.com/20240508/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://precisionbiosciences.com/20240508/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://precisionbiosciences.com/20240508/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 13 0000950170-24-055089-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-055089-xbrl.zip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dtil-20240508_htm.xml IDEA: XBRL DOCUMENT 0001357874 2024-05-08 2024-05-08 false 0001357874 NASDAQ 8-K 2024-05-08 Precision BioSciences, Inc. DE 001-38841 20-4206017 302 East Pettigrew St. Suite A-100 Durham NC 27701 919 314-5512 false false false false Common stock, par value $0.000005 per share DTIL true false